153 related articles for article (PubMed ID: 28462649)
21. Does a high Mandard score really define a poor response to chemotherapy in oesophageal adenocarcinoma?
Knight WRC; Baker CR; Griffin N; Wulaningsih W; Kelly M; Davies AR; Gossage JA;
Br J Cancer; 2021 May; 124(10):1653-1660. PubMed ID: 33742143
[TBL] [Abstract][Full Text] [Related]
22. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
[TBL] [Abstract][Full Text] [Related]
23. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
[TBL] [Abstract][Full Text] [Related]
24. The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis.
Parry K; van Rossum PS; Haj Mohammad N; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2017 Jan; 43(1):226-233. PubMed ID: 27424786
[TBL] [Abstract][Full Text] [Related]
25. Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.
Sirohi B; Barreto SG; Singh A; Batra S; Mittra A; Rastogia S; Ramadwar M; Shetty N; Goel M; Shrikhande SV
J Cancer Res Ther; 2014; 10(4):866-70. PubMed ID: 25579520
[TBL] [Abstract][Full Text] [Related]
26. Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma.
Davies AR; Myoteri D; Zylstra J; Baker CR; Wulaningsih W; Van Hemelrijck M; Maisey N; Allum WH; Smyth E; Gossage JA; Lagergren J; Cunningham D; Green M;
Br J Surg; 2018 Nov; 105(12):1639-1649. PubMed ID: 30047556
[TBL] [Abstract][Full Text] [Related]
27. Identification of plasma proteins associated with oesophageal cancer chemotherapeutic treatment outcomes using SWATH-MS.
Guo N; Minas G; Synowsky SA; Dunne MR; Ahmed H; McShane R; Bhardwaj A; Donlon NE; Lorton C; O'Sullivan J; Reynolds JV; Caie PD; Shirran SL; Lynch AG; Stewart AJ; Arya S
J Proteomics; 2022 Aug; 266():104684. PubMed ID: 35842220
[TBL] [Abstract][Full Text] [Related]
28. Prospective cohort study of neoadjuvant therapy toxicity in the treatment of oesophageal adenocarcinoma.
Bunting D; Berrisford R; Wheatley T; Humphreys L; Ariyarathenam A; Sanders G
Int J Surg; 2018 Apr; 52():126-130. PubMed ID: 29455047
[TBL] [Abstract][Full Text] [Related]
29. Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis.
Thomas M; Borggreve AS; van Rossum PSN; Perneel C; Moons J; Van Daele E; van Hillegersberg R; Deng W; Pattyn P; Mook S; Boterberg T; Ruurda JP; Nafteux P; Lin SH; Haustermans K
Acta Oncol; 2019 Oct; 58(10):1358-1365. PubMed ID: 31432736
[No Abstract] [Full Text] [Related]
30. Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03).
Athauda A; Nankivell M; Langley RE; Alderson D; Allum W; Grabsch HI; Starling N; Chau I; Cunningham D
Eur J Cancer; 2020 Sep; 137():45-56. PubMed ID: 32745964
[TBL] [Abstract][Full Text] [Related]
31. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemoradiation for patients with advanced oesophageal cancer - which response grading system best impacts prognostic discrimination?
Puetz K; Bollschweiler E; Semrau R; Mönig SP; Hölscher AH; Drebber U
Histopathology; 2019 Apr; 74(5):731-743. PubMed ID: 30636069
[TBL] [Abstract][Full Text] [Related]
33. Comparative Investigation of Postoperative Complications in Patients With Gastroesophageal Junction Cancer Treated With Preoperative Chemotherapy or Surgery Alone.
Achiam MP; Jensen LB; Larsson H; Jensen LS; Larsen AC; Holm J; Svendsen LB
Scand J Surg; 2016 Mar; 105(1):22-8. PubMed ID: 25794689
[TBL] [Abstract][Full Text] [Related]
34. Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer.
Sylvie L; Silvia S; Salah-Eddin AB; Markus F; Florian L; Peter TP; Bernhard H; Martin A; Alexander N
Eur J Cancer; 2015 Sep; 51(14):1918-26. PubMed ID: 26216588
[TBL] [Abstract][Full Text] [Related]
35. Systemic inflammatory markers and outcome in patients with locally advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Jagadesham VP; Lagarde SM; Immanuel A; Griffin SM
Br J Surg; 2017 Mar; 104(4):401-407. PubMed ID: 28072456
[TBL] [Abstract][Full Text] [Related]
36. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
37. Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma.
Powell AGMT; Chin C; Coxon AH; Chalishazar A; Christian A; Roberts SA; Lewis WG
BJS Open; 2020 Jun; 4(3):416-423. PubMed ID: 32232963
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
Kamarajah SK; Phillips AW; Ferri L; Hofstetter WL; Markar SR
Br J Surg; 2021 Apr; 108(4):403-411. PubMed ID: 33755097
[TBL] [Abstract][Full Text] [Related]
39. Caspase-cleaved cytokeratin-18 and tumour regression in gastro-oesophageal adenocarcinomas treated with neoadjuvant chemotherapy.
Fareed KR; Soomro IN; Hameed K; Arora A; Lobo DN; Parsons SL; Madhusudan S
World J Gastroenterol; 2012 Apr; 18(16):1915-20. PubMed ID: 22563171
[TBL] [Abstract][Full Text] [Related]
40. Real-life data on improvement of survival after perioperative chemotherapy versus surgery alone on resectable adenocarcinoma of the stomach - a single-center study.
Kuhnle PJ; Israel KF; Menges M
Z Gastroenterol; 2019 May; 57(5):606-610. PubMed ID: 31083749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
